Effects of acute abstinence, reinstatement, and mecamylamine on biochemical and behavioral measures of cigarette smoking in schizophrenia
- PMID: 17293085
- PMCID: PMC1913717
- DOI: 10.1016/j.schres.2006.12.007
Effects of acute abstinence, reinstatement, and mecamylamine on biochemical and behavioral measures of cigarette smoking in schizophrenia
Abstract
Background: Schizophrenics have higher rates of smoking than the general population, and more difficulty with smoking cessation. However, there has been little study of differences between schizophrenics and controls with respect to biochemical and behavioral indices of smoking. We compared smokers with schizophrenia (SS; n=27) and control smokers (CS; n=26) on smoking and psychiatric outcomes at baseline, during acute smoking abstinence and reinstatement, and with pre-treatment using the nicotinic acetylcholine receptor (nAChR) antagonist mecamylamine (MEC) in a human laboratory setting.
Methods: Biochemical (e.g., plasma nicotine) and behavioral (e.g., craving, withdrawal) outcomes were assessed at baseline, after overnight abstinence, and after smoking reinstatement during three consecutive test weeks. Each week, participants received one of three doses of MEC (0.0, 5.0, or 10.0 mg/dayx3 days) in a randomized, counterbalanced manner.
Results: Compared to CS, SS displayed similar levels of craving and withdrawal, but higher plasma nicotine and cotinine levels, and cotinine/CPD ratio. During reinstatement, SS consumed significantly more cigarettes than CS, but MEC did not significantly alter indices of smoking, psychiatric symptoms, or cigarette consumption during reinstatement.
Conclusions: 1) The reinforcing effects of smoking may be increased in SS versus CS after overnight abstinence; 2) the lack of effects of nAChR antagonism may suggest that non-nicotinic components of cigarettes may contribute to the behavioral effects of smoking in both SS and CS; and 3) consistent with previous studies, SS may exhibit higher baseline levels of nicotine and cotinine, and greater extraction of nicotine per cigarette than CS.
Figures
Similar articles
-
Effects of the nicotinic receptor antagonist mecamylamine on ad-lib smoking behavior, topography, and nicotine levels in smokers with and without schizophrenia: a preliminary study.Schizophr Res. 2009 Dec;115(2-3):317-24. doi: 10.1016/j.schres.2009.07.019. Epub 2009 Aug 22. Schizophr Res. 2009. PMID: 19700263 Free PMC article. Clinical Trial.
-
Effects of cigarette smoking on spatial working memory and attentional deficits in schizophrenia: involvement of nicotinic receptor mechanisms.Arch Gen Psychiatry. 2005 Jun;62(6):649-59. doi: 10.1001/archpsyc.62.6.649. Arch Gen Psychiatry. 2005. PMID: 15939842
-
A preliminary study of the effects of cigarette smoking on prepulse inhibition in schizophrenia: involvement of nicotinic receptor mechanisms.Schizophr Res. 2006 Oct;87(1-3):307-15. doi: 10.1016/j.schres.2006.05.022. Epub 2006 Jul 18. Schizophr Res. 2006. PMID: 16854565
-
A review of the efficacy of smoking-cessation pharmacotherapies in nonwhite populations.Clin Ther. 2008 May;30(5):800-12. doi: 10.1016/j.clinthera.2008.05.010. Clin Ther. 2008. PMID: 18555928 Review.
-
Disrupting nicotine reinforcement: from cigarette to brain.Ann N Y Acad Sci. 2008 Oct;1141:233-56. doi: 10.1196/annals.1441.019. Ann N Y Acad Sci. 2008. PMID: 18991961 Review.
Cited by
-
Effects of the nicotinic receptor antagonist mecamylamine on ad-lib smoking behavior, topography, and nicotine levels in smokers with and without schizophrenia: a preliminary study.Schizophr Res. 2009 Dec;115(2-3):317-24. doi: 10.1016/j.schres.2009.07.019. Epub 2009 Aug 22. Schizophr Res. 2009. PMID: 19700263 Free PMC article. Clinical Trial.
-
Acute Psychosis in Withdrawal from Nicotine Vaping in a Young Man with Comorbid Diabetic Ketoacidosis and Cannabis Use.Case Rep Psychiatry. 2020 Jun 3;2020:5710810. doi: 10.1155/2020/5710810. eCollection 2020. Case Rep Psychiatry. 2020. PMID: 32566348 Free PMC article.
-
Stop Turning a Blind Eye: Tobacco Smoking Among Egyptian Patients With Schizophrenia.Front Psychiatry. 2019 Jan 4;9:703. doi: 10.3389/fpsyt.2018.00703. eCollection 2018. Front Psychiatry. 2019. PMID: 30687137 Free PMC article.
-
Reduced nicotine product standards for combustible tobacco: building an empirical basis for effective regulation.Prev Med. 2014 Nov;68:17-22. doi: 10.1016/j.ypmed.2014.06.020. Epub 2014 Jun 23. Prev Med. 2014. PMID: 24967958 Free PMC article. Review.
-
Prefrontal cognitive dysfunction is associated with tobacco dependence treatment failure in smokers with schizophrenia.Drug Alcohol Depend. 2009 Sep 1;104(1-2):94-9. doi: 10.1016/j.drugalcdep.2009.04.005. Epub 2009 May 17. Drug Alcohol Depend. 2009. PMID: 19447570 Free PMC article. Clinical Trial.
References
-
- Adler LE, Hoffer LD, Wiser A, Freedman R. Normalization of auditory physiology by cigarette smoking in schizophrenic patients. American Journal of Psychiatry. 1993;150:1856–1861. - PubMed
-
- Beck AT, Steer RA. Beck Depression Inventory. Center for Cognitive Therapy; Philadelphia, PA: 1987.
-
- Beck AT, Steer RA, Garbin MG. Psychometric properties of the Beck Depression Inventory: Twenty-five years of evaluation. Clinical Psychology Review. 1988;8:77–100.
-
- Benowitz NL, Jacob P, III, Ahijevich K, Jarvis MJ, Hall S, LeHouzec J, Lichenstein E, Henningfield J, Tsoh J, Hurt RD, Velicer W. Biochemical verification of tobacco use and cessation. Report from the SRNT Subcommittee on Biochemical Verification. Nicotine & Tobacco Research. 2002;4:149–159. - PubMed
-
- Breese CR, Lee MJ, Adams CE, Sullivan B, Logel J, Gillen KM, Marks MJ, Collins AC, Leonard S. Abnormal regulation of high-affinity nicotinic receptors in subjects with schizophrenia. Neuropsychopharmacol. 2000;23:351–364. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical